This robust study on changes in gene expressions after treatment with beta 3-adrenergic receptor agonist, highlights novel findings for better understanding of pathophysiology of T2D in MKR mice, and identifies potential treatment targets. The gene discussed is ADRB3; the disease is type 2 diabetes mellitus.